Dyne Therapeutics Inc. (DYN) NASDAQ

$11.13 0.25 (2.25%)

Market Cap: $612.96M

As of 03/28/23 03:59 PM EDT. Market closed.

(DYN)

Dyne Therapeutics Inc. (DYN)
NASDAQ

$11.13
0.25 (2.25%)

Market Cap: $612.96M

As of 03/28/23 03:59 PM EDT. Market closed.

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United ... read more

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$950,000
CEO Compensation (Total)
$6.94M
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
93
CEO Compensation (Base)
$950,000
CEO Compensation (Total)
$6.94M
Address
.
PRICE CHART FOR DYNE THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$11.02
Previous Close
$10.88
Days Range
$10.80 - $11.70
52 week range
$4.30 - $15.63
Volume
157,631
Avg. Volume (30 days)
394,427
Market Cap
$612.96M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
56,338,214
Open
$11.02
Previous Close
$10.88
Days Range
$10.80 - $11.70
52 week range
$4.30 - $15.63
Volume
157,631
Avg. Volume (30 days)
394,427
Market Cap
$612.96M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
56,338,214

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR DYNE THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Scalzo Richard WilliamSee RemarksMar 14, 2023 Sale$13.331,31117,47654,872Mar 15, 2023, 05:51 PM
McNeill JonathanSee RemarksMar 14, 2023 Sale$13.331,20916,11665,391Mar 15, 2023, 05:50 PM
McNeill JonathanSee RemarksMar 13, 2023 Sale$13.001,00013,00066,600Mar 15, 2023, 05:50 PM
HIGH SUSANNA GATTIChief Operating OfficerMar 14, 2023 Sale$13.331,55920,781110,476Mar 15, 2023, 05:50 PM
Farwell WildonChief Medical OfficerMar 14, 2023 Sale$13.337,44199,18992,655Mar 15, 2023, 05:49 PM
Brumm Joshua TSee RemarksMar 14, 2023 Sale$13.337,31897,549322,483Mar 15, 2023, 05:49 PM
Beskrovnaya OxanaChief Scientific OfficerMar 14, 2023 Sale$13.331,41618,87588,729Mar 15, 2023, 05:48 PM
McNeill JonathanSee RemarksJan 18, 2023 Option Exercise$0.7310,0007,30077,600Jan 23, 2023, 08:27 AM
McNeill JonathanSee RemarksJan 18, 2023 Sale$14.0310,000140,30067,600Jan 23, 2023, 08:27 AM
McNeill JonathanSee RemarksJan 09, 2023 Sale$11.5730,150348,83567,600Jan 11, 2023, 04:56 PM
Rhodes Jason PDirectorDec 12, 2022 Buy$10.70934,58110,000,017934,581Dec 14, 2022, 04:56 PM
Atlas Venture Opportunity Fund II, L.P.10% OwnerDec 12, 2022 Buy$10.70934,58110,000,017934,581Dec 14, 2022, 04:55 PM
Scalzo Richard WilliamSee RemarksDec 12, 2022 Sale$10.873123,39156,183Dec 13, 2022, 05:06 PM
McNeill JonathanSee RemarksDec 12, 2022 Sale$10.874725,13197,750Dec 13, 2022, 05:05 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 12, 2022 Sale$10.877518,163112,035Dec 13, 2022, 05:05 PM
Farwell WildonChief Medical OfficerDec 12, 2022 Sale$10.876286,826100,096Dec 13, 2022, 05:04 PM
Brumm Joshua TSee RemarksDec 12, 2022 Sale$10.873,32236,110329,801Dec 13, 2022, 05:04 PM
Beskrovnaya OxanaChief Scientific OfficerDec 12, 2022 Sale$10.876807,39290,145Dec 13, 2022, 05:03 PM
Brumm Joshua TSee RemarksOct 10, 2022 Option Exercise$1.03195,800201,674400,423Oct 11, 2022, 09:00 AM
Brumm Joshua TSee RemarksOct 07, 2022 Option Exercise$1.0314,20014,626218,823Oct 11, 2022, 09:00 AM
Brumm Joshua TSee RemarksOct 10, 2022 Sale$12.46195,8002,439,668204,623Oct 11, 2022, 09:00 AM
Brumm Joshua TSee RemarksOct 07, 2022 Sale$13.3714,200189,854204,623Oct 11, 2022, 09:00 AM
Scalzo Richard WilliamSee RemarksSep 20, 2022 Option Exercise$13.7084011,50825,495Sep 21, 2022, 04:09 PM
McNeill JonathanSee RemarksSep 20, 2022 Option Exercise$13.701,24617,07058,222Sep 21, 2022, 04:08 PM
HIGH SUSANNA GATTIChief Operating OfficerSep 20, 2022 Option Exercise$13.702,62936,01768,786Sep 21, 2022, 04:08 PM
Brumm Joshua TSee RemarksSep 20, 2022 Option Exercise$13.7011,836162,153204,623Sep 21, 2022, 04:07 PM
Beskrovnaya OxanaChief Scientific OfficerSep 20, 2022 Option Exercise$13.701,41319,35850,825Sep 21, 2022, 04:07 PM
Scalzo Richard WilliamSee RemarksSep 15, 2022 Option Exercise$14.053264,58026,335Sep 15, 2022, 05:30 PM
Farwell WildonChief Medical OfficerSep 15, 2022 Option Exercise$14.056589,24564,724Sep 15, 2022, 05:28 PM
McNeill JonathanSee RemarksSep 15, 2022 Option Exercise$14.054946,94159,468Sep 15, 2022, 05:27 PM
HIGH SUSANNA GATTIChief Operating OfficerSep 15, 2022 Option Exercise$14.0578611,04371,415Sep 15, 2022, 05:26 PM
Brumm Joshua TSee RemarksSep 15, 2022 Option Exercise$14.053,48048,894216,459Sep 15, 2022, 05:25 PM
Beskrovnaya OxanaChief Scientific OfficerSep 15, 2022 Option Exercise$14.0571210,00452,238Sep 15, 2022, 05:24 PM
Brumm Joshua TSee RemarksJul 06, 2022 Option Exercise$8.2410,96390,335219,939Jul 06, 2022, 06:18 PM
Scalzo Richard WilliamSee RemarksJun 14, 2022 Option Exercise$4.953331,64826,661Jun 15, 2022, 08:05 PM
McNeill JonathanSee RemarksJun 14, 2022 Option Exercise$4.955042,49559,962Jun 15, 2022, 08:04 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 14, 2022 Option Exercise$4.958023,97072,201Jun 15, 2022, 08:03 PM
Farwell WildonChief Medical OfficerJun 14, 2022 Option Exercise$4.956683,30765,382Jun 15, 2022, 08:03 PM
Brumm Joshua TSee RemarksJun 14, 2022 Option Exercise$4.953,54017,523206,784Jun 15, 2022, 08:02 PM
Beskrovnaya OxanaChief Scientific OfficerJun 14, 2022 Option Exercise$4.957263,59452,950Jun 15, 2022, 08:02 PM
Scalzo Richard WilliamSee RemarksMar 11, 2022 Sale$8.733082,68926,994Mar 14, 2022, 05:09 PM
McNeill JonathanSee RemarksMar 11, 2022 Sale$8.734814,19960,466Mar 14, 2022, 05:09 PM
HIGH SUSANNA GATTIChief Operating OfficerMar 11, 2022 Sale$8.737656,67873,003Mar 14, 2022, 05:08 PM
Farwell WildonChief Medical OfficerMar 11, 2022 Sale$8.736405,58766,050Mar 14, 2022, 05:08 PM
Brumm Joshua TSee RemarksMar 11, 2022 Sale$8.733,38429,542210,324Mar 14, 2022, 05:07 PM
Beskrovnaya OxanaChief Scientific OfficerMar 11, 2022 Sale$8.736936,05053,676Mar 14, 2022, 05:06 PM
Farwell WildonChief Medical OfficerMar 02, 2022 Sale$8.565,61748,08266,690Mar 03, 2022, 07:22 PM
HIGH SUSANNA GATTIChief Operating OfficerSep 23, 2021 Sale$17.222,45142,20633,453Sep 24, 2021, 10:50 AM
Scalzo Richard WilliamSee RemarksSep 21, 2021 Sale$16.114927,92610,606Sep 22, 2021, 08:03 PM
Scalzo Richard WilliamSee RemarksSep 20, 2021 Sale$15.613675,72911,098Sep 22, 2021, 08:03 PM
McNeill JonathanSee RemarksSep 21, 2021 Sale$16.1172911,74435,636Sep 22, 2021, 08:02 PM
McNeill JonathanSee RemarksSep 20, 2021 Sale$15.615458,50736,365Sep 22, 2021, 08:02 PM
Brumm Joshua TSee RemarksSep 21, 2021 Sale$16.114,58473,84899,018Sep 22, 2021, 08:02 PM
Brumm Joshua TSee RemarksSep 20, 2021 Sale$15.613,42553,464103,602Sep 22, 2021, 08:02 PM
Beskrovnaya OxanaChief Scientific OfficerSep 21, 2021 Sale$16.1182713,32317,845Sep 22, 2021, 08:01 PM
Beskrovnaya OxanaChief Scientific OfficerSep 20, 2021 Sale$15.616179,63118,672Sep 22, 2021, 08:01 PM
VV Manager II, LLC10% OwnerSep 21, 2020 Buy$19.00792,99515,066,9052,880,125Sep 23, 2020, 07:11 PM
VV Manager II, LLC10% OwnerSep 21, 2020 Buy$19.0022,005418,09579,921Sep 23, 2020, 07:11 PM
Logos Global Management LP10% OwnerSep 21, 2020 Buy$19.00700,00013,300,0001,504,392Sep 23, 2020, 07:09 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerSep 21, 2020 Buy$19.00660,00012,540,0002,805,045Sep 23, 2020, 06:55 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Scalzo Richard WilliamSee Remarks03/14/202317,476
McNeill JonathanSee Remarks03/14/202316,116
McNeill JonathanSee Remarks03/13/202313,000
HIGH SUSANNA GATTIChief Operating Officer03/14/202320,781
Farwell WildonChief Medical Officer03/14/202399,189
Brumm Joshua TSee Remarks03/14/202397,549
Beskrovnaya OxanaChief Scientific Officer03/14/202318,875
McNeill JonathanSee Remarks01/18/20237,300
McNeill JonathanSee Remarks01/18/2023140,300
McNeill JonathanSee Remarks01/09/2023348,835
Rhodes Jason PDirector12/12/202210,000,017
Atlas Venture Opportunity Fund II, L.P.10% Owner12/12/202210,000,017
Scalzo Richard WilliamSee Remarks12/12/20223,391
McNeill JonathanSee Remarks12/12/20225,131
HIGH SUSANNA GATTIChief Operating Officer12/12/20228,163
Farwell WildonChief Medical Officer12/12/20226,826
Brumm Joshua TSee Remarks12/12/202236,110
Beskrovnaya OxanaChief Scientific Officer12/12/20227,392
Brumm Joshua TSee Remarks10/10/2022201,674
Brumm Joshua TSee Remarks10/07/202214,626
Brumm Joshua TSee Remarks10/10/20222,439,668
Brumm Joshua TSee Remarks10/07/2022189,854
Scalzo Richard WilliamSee Remarks09/20/202211,508
McNeill JonathanSee Remarks09/20/202217,070
HIGH SUSANNA GATTIChief Operating Officer09/20/202236,017
Brumm Joshua TSee Remarks09/20/2022162,153
Beskrovnaya OxanaChief Scientific Officer09/20/202219,358
Scalzo Richard WilliamSee Remarks09/15/20224,580
Farwell WildonChief Medical Officer09/15/20229,245
McNeill JonathanSee Remarks09/15/20226,941
HIGH SUSANNA GATTIChief Operating Officer09/15/202211,043
Brumm Joshua TSee Remarks09/15/202248,894
Beskrovnaya OxanaChief Scientific Officer09/15/202210,004
Brumm Joshua TSee Remarks07/06/202290,335
Scalzo Richard WilliamSee Remarks06/14/20221,648
McNeill JonathanSee Remarks06/14/20222,495
HIGH SUSANNA GATTIChief Operating Officer06/14/20223,970
Farwell WildonChief Medical Officer06/14/20223,307
Brumm Joshua TSee Remarks06/14/202217,523
Beskrovnaya OxanaChief Scientific Officer06/14/20223,594
Scalzo Richard WilliamSee Remarks03/11/20222,689
McNeill JonathanSee Remarks03/11/20224,199
HIGH SUSANNA GATTIChief Operating Officer03/11/20226,678
Farwell WildonChief Medical Officer03/11/20225,587
Brumm Joshua TSee Remarks03/11/202229,542
Beskrovnaya OxanaChief Scientific Officer03/11/20226,050
Farwell WildonChief Medical Officer03/02/202248,082
HIGH SUSANNA GATTIChief Operating Officer09/23/202142,206
Scalzo Richard WilliamSee Remarks09/21/20217,926
Scalzo Richard WilliamSee Remarks09/20/20215,729
McNeill JonathanSee Remarks09/21/202111,744
McNeill JonathanSee Remarks09/20/20218,507
Brumm Joshua TSee Remarks09/21/202173,848
Brumm Joshua TSee Remarks09/20/202153,464
Beskrovnaya OxanaChief Scientific Officer09/21/202113,323
Beskrovnaya OxanaChief Scientific Officer09/20/20219,631
VV Manager II, LLC10% Owner09/21/202015,066,905
VV Manager II, LLC10% Owner09/21/2020418,095
Logos Global Management LP10% Owner09/21/202013,300,000
RA CAPITAL MANAGEMENT, L.P.10% Owner09/21/202012,540,000
Load More Insider Transactions
FUNDS WITH A POSITION IN DYNE THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.2,618,6180.00095%3.7%Other
HHLR ADVISORS, LTD.939,6480.23%-6.04%Other
CANDRIAM S.C.A.633,6240.05%53.19%Other
VIVO CAPITAL, LLC577,6420.77%No changeOther
GEODE CAPITAL MANAGEMENT, LLC546,5550.00089%2.42%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.400,0000.01%-11.11%Other
ORBIMED ADVISORS LLC220,4000.05%ExitedOther
UBS OCONNOR LLC208,1910.07%17.96%Value
RENAISSANCE TECHNOLOGIES LLC107,7000.00171%2.67%Other
TUDOR INVESTMENT CORP ET AL60,2570.01%129.99%Event Driven, Other
D. E. SHAW & CO., INC.13,2460.00017%NewOther
BlackRock Inc.2,593,524nan%NewOther
CHANGE IN SHARES OUTSTANDING FOR DYNE THERAPEUTICS INC
STOCK BUYBACKS FOR DYNE THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2022
09/30/2022
8.08%
1Q

Period of Report: 12/31/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2022
8.08%
1Q